Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.
暂无分享,去创建一个
A. Khorana | J. Schein | J. Berger | P. Wells | S. Kaatz | P. Lefebvre | F. Laliberté | C. Crivera | P. Wildgoose | V. Ashton | D. Lejeune | R. Seheult
[1] A. Cohen,et al. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis , 2016, PloS one.
[2] A. Bianco,et al. Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials. , 2016, Thrombosis research.
[3] E. Stuart,et al. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.
[4] J. Mega,et al. Duration of Anticoagulation for Venous Thromboembolic Events , 2014, Circulation.
[5] W. Olson,et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients , 2014, Current medical research and opinion.
[6] E. Akl,et al. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. , 2014, Blood.
[7] A. Cohen. Long-term benefits of preventing venous thromboembolic events , 2012, Current medical research and opinion.
[8] A. Cohen,et al. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism , 2012, Thrombosis and Haemostasis.
[9] Elie A Akl,et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.
[10] Elie A Akl,et al. Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .
[11] Paolo Prandoni,et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[12] W. Ageno,et al. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study) , 2011, Expert review of cardiovascular therapy.
[13] W. Ray,et al. An automated database case definition for serious bleeding related to oral anticoagulant use , 2011, Pharmacoepidemiology and drug safety.
[14] Bruce L Davidson,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.
[15] Peter C. Austin,et al. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..
[16] J. Emmerich,et al. Venous Thromboembolism: Risk Factors for Recurrence , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[17] M. Monreal,et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry , 2008, Thrombosis and Haemostasis.
[18] John A. Heit,et al. The epidemiology of venous thromboembolism , 2003, Journal of Thrombosis and Thrombolysis.
[19] C. Kearon,et al. Natural History of Venous Thromboembolism , 2003, Circulation.
[20] R. White,et al. The epidemiology of venous thromboembolism. , 2003, Circulation.
[21] H. Eriksson,et al. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. , 2000, Archives of internal medicine.
[22] G. Guyatt,et al. Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .
[23] C. Kearon. Natural History of Venous Thromboembolism , 2001, Seminars in vascular medicine.